Full Press Release Details
A$2.6 million R&D Tax Incentive from French Government
SYDNEY, AUSTRALIA 7 December 2023
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune
diseases, is pleased to announce it has received a 1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Cr dit d Imp t Recherche scheme (CIR).
The Cr dit d Imp t Recherche (CIR), meaning Research Tax Credit , is a French government tax incentive by which
French companies conducting research and development activities in Europe can be reimbursed 30% of their eligible expenditure.
Immutep qualifies for the
CIR tax incentive through its subsidiary Immutep S.A.S. due to the research and development conducted in its laboratory in France. The cash payment is provided in respect of expenditure incurred on eligible R&D activities conducted in the
European Union in the 2022 calendar year. Immutep also qualifies for cash rebates from the Australian Federal Government s R&D tax incentive program in respect of expenditure incurred on eligible R&D activities conducted in Australia.
As previously announced, in October 2023, the company received an A$1.13 million cash rebate from the Australian Federal Government s R&D tax incentive program for the eligible R&D activities conducted in financial year 2022.
The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761.
Immutep is a clinical-stage biotechnology
company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
+61 (0)406 759 268; cstrong@citadelmagnus.com
U.S. Investors/Media:
Chris Basta, VP, Investor
Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
Level 33, Australia Square
264 George Street, Sydney NSW 2000